These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27749322)

  • 1. Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.
    Danila DC; Samoila A; Patel C; Schreiber N; Herkal A; Anand A; Bastos D; Heller G; Fleisher M; Scher HI
    Cancer J; 2016; 22(5):315-320. PubMed ID: 27749322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.
    Danila DC; Anand A; Schultz N; Heller G; Wan M; Sung CC; Dai C; Khanin R; Fleisher M; Lilja H; Scher HI
    Eur Urol; 2014 Jun; 65(6):1191-7. PubMed ID: 23954088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
    Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
    Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer.
    Škereňová M; Mikulová V; Čapoun O; Švec D; Kološtová K; Soukup V; Honová H; Hanuš T; Zima T
    Mol Diagn Ther; 2018 Jun; 22(3):381-390. PubMed ID: 29725990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system.
    Andreopoulou E; Yang LY; Rangel KM; Reuben JM; Hsu L; Krishnamurthy S; Valero V; Fritsche HA; Cristofanilli M
    Int J Cancer; 2012 Apr; 130(7):1590-7. PubMed ID: 21469140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest.
    Liu HE; Vuppalapaty M; Hoerner CR; Bergstrom CP; Chiu M; Lemaire C; Che J; Kaur A; Dimmick A; Liu S; Metzner TJ; Araya M; Crouse S; Sprenger-Haussels M; Schlumpberger M; Leppert JT; Hauch S; Sollier E; Fan AC
    BMC Cancer; 2024 Apr; 24(1):482. PubMed ID: 38627648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
    Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
    Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®.
    Gorges TM; Stein A; Quidde J; Hauch S; Röck K; Riethdorf S; Joosse SA; Pantel K
    PLoS One; 2016; 11(5):e0155126. PubMed ID: 27182774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.
    Helo P; Cronin AM; Danila DC; Wenske S; Gonzalez-Espinoza R; Anand A; Koscuiszka M; Väänänen RM; Pettersson K; Chun FK; Steuber T; Huland H; Guillonneau BD; Eastham JA; Scardino PT; Fleisher M; Scher HI; Lilja H
    Clin Chem; 2009 Apr; 55(4):765-73. PubMed ID: 19233911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest® System for Detection of Circulating Tumor Cells.
    Čapoun O; Mikulová V; Jančíková M; Honová H; Kološtová K; Sobotka R; Michael P; Zima T; Hanuš T; Soukup V
    Anticancer Res; 2016 Apr; 36(4):2019-26. PubMed ID: 27069196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
    Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T;
    Breast Cancer Res; 2012 Aug; 14(4):R118. PubMed ID: 22894854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.
    Russo GI; Bier S; Hennenlotter J; Beger G; Pavlenco L; van de Flierdt J; Hauch S; Maas M; Walz S; Rausch S; Bedke J; Morgia G; Stenzl A; Todenhöfer T
    BJU Int; 2018 Jul; 122(1):152-159. PubMed ID: 29542849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
    Scher HI; Armstrong AJ; Schonhoft JD; Gill A; Zhao JL; Barnett E; Carbone E; Lu J; Antonarakis ES; Luo J; Tagawa S; Dos Anjos CH; Yang Q; George D; Szmulewitz R; Danila DC; Wenstrup R; Gonen M; Halabi S
    Eur J Cancer; 2021 Jun; 150():83-94. PubMed ID: 33894633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
    McDaniel AS; Ferraldeschi R; Krupa R; Landers M; Graf R; Louw J; Jendrisak A; Bales N; Marrinucci D; Zafeiriou Z; Flohr P; Sideris S; Crespo M; Figueiredo I; Mateo J; de Bono JS; Dittamore R; Tomlins SA; Attard G
    BJU Int; 2017 Nov; 120(5B):E30-E44. PubMed ID: 27539393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.
    Thalgott M; Heck MM; Eiber M; Souvatzoglou M; Hatzichristodoulou G; Kehl V; Krause BJ; Rack B; Retz M; Gschwend JE; Andergassen U; Nawroth R
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1457-64. PubMed ID: 25708944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
    Friedlander TW; Ngo VT; Dong H; Premasekharan G; Weinberg V; Doty S; Zhao Q; Gilbert EG; Ryan CJ; Chen WT; Paris PL
    Int J Cancer; 2014 May; 134(10):2284-93. PubMed ID: 24166007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
    Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
    Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.
    Massard C; Oulhen M; Le Moulec S; Auger N; Foulon S; Abou-Lovergne A; Billiot F; Valent A; Marty V; Loriot Y; Fizazi K; Vielh P; Farace F
    Oncotarget; 2016 Aug; 7(34):55069-55082. PubMed ID: 27391263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.